Takeda to Voluntarily Withdraw Mobocertinib for EGFR Exon 20 Insertion NSCLC | OncLive
Takeda has announced plans to voluntarily withdraw mobocertinib in the United States for adult patients with EGFR exon 20 insertion mutation–positive, locally advanced or metastatic non–small cell...
onclive.com